Terry J. Rosen Buys 19,800 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CEO Terry J. Rosen acquired 19,800 shares of the business's stock in a transaction on Thursday, February 27th. The stock was acquired at an average price of $10.18 per share, with a total value of $201,564.00. Following the acquisition, the chief executive officer now owns 2,554,160 shares in the company, valued at $26,001,348.80. The trade was a 0.78 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Arcus Biosciences Stock Down 3.3 %

Shares of RCUS traded down $0.36 during mid-day trading on Monday, hitting $10.53. 1,116,764 shares of the company's stock were exchanged, compared to its average volume of 705,183. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. Arcus Biosciences, Inc. has a fifty-two week low of $9.86 and a fifty-two week high of $19.69. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -3.34 and a beta of 0.84. The stock's 50-day moving average is $13.37 and its 200-day moving average is $15.40.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.17) by $0.14. The company had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. On average, sell-side analysts anticipate that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Woodline Partners LP increased its stake in Arcus Biosciences by 1.3% in the fourth quarter. Woodline Partners LP now owns 3,523,937 shares of the company's stock valued at $52,471,000 after purchasing an additional 45,497 shares during the last quarter. Two Sigma Advisers LP lifted its holdings in shares of Arcus Biosciences by 35.8% in the 4th quarter. Two Sigma Advisers LP now owns 58,800 shares of the company's stock valued at $876,000 after purchasing an additional 15,500 shares during the last quarter. Two Sigma Investments LP boosted its position in shares of Arcus Biosciences by 8.1% in the 4th quarter. Two Sigma Investments LP now owns 146,686 shares of the company's stock valued at $2,184,000 after purchasing an additional 11,027 shares during the period. Tema Etfs LLC purchased a new position in Arcus Biosciences during the 4th quarter worth approximately $331,000. Finally, ProShare Advisors LLC increased its position in Arcus Biosciences by 44.4% during the fourth quarter. ProShare Advisors LLC now owns 16,379 shares of the company's stock worth $244,000 after buying an additional 5,038 shares during the period. 92.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RCUS has been the topic of several analyst reports. HC Wainwright upgraded Arcus Biosciences from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $18.00 to $24.00 in a report on Wednesday, February 26th. Morgan Stanley cut their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Wedbush reiterated an "outperform" rating and issued a $36.00 target price on shares of Arcus Biosciences in a report on Thursday, November 7th. Finally, Bank of America cut their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a report on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $30.25.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.